JS25

JS25 is a selective and covalent inhibitor of BTK that inactivates BTK with an IC50 value of 5.8 nM by chelating Tyr551. JS25 inhibits cancer cells proliferation, pronounces cell death, and promotes murine xenograft model of Burkitt’s lymphoma. JS25 effectively crosses the blood-brain barrier[1].

Product Specifications

CAS Number

[2411771-95-2]

UNSPSC

12352005

Target

Btk

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/js25.html

Purity

98.37

Solubility

DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

C=CC(NC1=CC(C)=CC(N2C(C=CC3=C2C4=C(N=C3)C=C(C=C4)C5=CC=C(C=C5)NS(C)(=O)=O)=O)=C1)=O

Molecular Formula

C29H24N4O4S

Molecular Weight

524.59

References & Citations

[1]Sousa B B, et al. Selective Inhibition of Bruton’s Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors[J]. ACS Pharmacology & Translational Science, 2022.